PRESS RELEASES

Date Title and Summary View
Toggle Summary Regulus Therapeutics Selected for Fierce 15 Top Biotech Companies
Regulus Therapeutics Selected for Fierce 15 Top Biotech Companies CAMBRIDGE, Mass. and CARLSBAD, Calif., June 24, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc.
View HTML
Toggle Summary Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University
Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University CAMBRIDGE, Mass. and CARLSBAD, Calif., May 6, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc.
View HTML
Toggle Summary GlaxoSmithKline and Regulus Therapeutics Form Strategic Alliance To Develop microRNA Targeted Therapeutics to Treat Inflammatory Diseases
Companies Announce Significant microRNA Therapeutics Collaboration
View HTML
Toggle Summary Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer
Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer CAMBRIDGE, Mass. and CARLSBAD, Calif., February 11, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc.
View HTML
Toggle Summary New RNAi Approach for In Vivo Therapeutic Silencing of MicroRNAs is Demonstrated by Alnylam and Rockefeller University Scientists
Findings Published in Nature Show Potential of Targeting MicroRNAs to Treat Diseases
View HTML
Toggle Summary Alnylam and Isis License Intellectual Property for MicroRNA Gene Involved in Hepatitis C Viral Infection
Role of MicroRNA-122 in Hepatitis C Infection Published in Science
View HTML
Toggle Summary Alnylam and Isis Receive Exclusive License to Key microRNA Patents for Therapeutic Applications
Alnylam and Isis Receive Exclusive License to Key microRNA Patents for Therapeutic Applications Intellectual Property From Max Planck Society Strengthens Companies’ Leadership Positions In RNA-Based Drug Discovery and Development CAMBRIDGE, Mass., and CARLSBAD, Calif., Oct.
View HTML